AMANTA
Amanta Healthcare Limited
If management delivers what it guided
arithmetic on filed guidance and past valuations · not a price target
AMANTA
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹169 today
BEAR
₹85
-50%
11.6% a year · 19.8x exit
BASE
₹136
-20%
20% a year · 29.6x exit
BULL
₹251
+49%
27.2% a year · 51.5x exit
Where the market has priced it
13x44x today538x
- the guided figure reached earnings through a low-confidence bridge
- this company has too little filed history for a multiple band of its own, so the exit multiple is the median of 39 Pharmaceuticals: Major peers
How these numbers are produced
| Earnings base | FY26 fiscal year EPS ₹3.83 (screener) |
|---|---|
| Guided growth | 20% a year, said on the call of 16-Feb-2026 · transcript |
| Read across as | operating: unlabelled growth figure, read as revenue — low confidence |
| Delivery calibration | 0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings |
| Exit multiple | 19.82x / 29.55x / 51.47x, this company’s own p20 / median / p80 across 39 filed years |
| Filed-industry peers | median 29.55x across 39 peers — the cross-check, not the input |
| Arithmetic | base EPS × (1 + guided growth × delivery)1 × exit multiple |
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.
What management said
from NSE earnings-call filings · extracted, not interpreted
generic growth 20%
Bhavesh Patel: No, next year I think 20% to 20% CAGR is for next two years, but next year we'll see sizeable increase.
Call 16-Feb-2026 · bridge confidence low · transcript PDF